Updates on Molecular Targeted Therapies for CNS Tumors

• Beste egile batzuk: Pan, Edward (Argitaratzailea)
• Formatua: Baliabide elektronikoa Liburu kapitulua
• Hizkuntza: ingelesa
• Argitaratua: MDPI - Multidisciplinary Digital Publishing Institute 2023
• Gaiak: Medicine; Oncology; glioblastoma molecular classification; ERK/MAPK pathway; PI3K/PTEN pathway; receptor tyrosine kinase; EGFR; PDGFRA; FGFR3; MET; EPHB2; NF1; immunotherapy; glioblastoma; blood-brain barrier; central nervous system; T cells; T lymphocytes; PCNSL; CNS lymphoma; methotrexate; novel therapies; novel therapeutics; neurofibromatosis; low grade glioma; plexiform neurofibroma; vestibular schwannoma; glioma; tumor mutation burden; neoantigen; immune score; germline mutation; antigen processing and presentation; ependymoma; subependymoma; RELA; YAP1; ZFTA; PFA; PFB; MYCN; Group A; Group B; myxopapillary; targeted therapy; diffuse midline gliomas; molecular targets; potential therapy development; intraparenchymal metastases; CNS disease; metastatic disease; tyrosine kinase inhibitors; monoclonal antibodies; Warburg effect; mass spectrometry; isotope labeling; cancer metabolism; pediatric brain tumor; adenosine; tumor microenvironment; A2AAR antagonist; immune evasion; adenosine receptors; bevacizumab; temozolomide; progression; biomarker; neoplastic; meningitis; leptomeningeal; chemotherapy; radiotherapy; intrathecal; GBM; U87MG; A172; Metformin; LPS; antioxidant; cell cycle arrest; apoptosis; low-grade glioma; preclinical models; IDH-mutant glioma; patient avatars; methylation; methylomics; G-CIMP; MGMT; DNMT; ATRX; H3K27M; CpG island; tumor suppressor; methyltransferases; histone acetylation; brain tumor; brain metastasis; lung cancer; lung malignancy; progression-free survival; epidermal growth factor receptor; lung carcinoma; molecular therapy; whole-brain radiation therapy; stereotactic radiosurgery; KIF11; n/a
• Sarrera elektronikoa: DOAB: download the publication; DOAB: description of the publication

The challenges in identifying effective therapies for CNS tumors continue to be daunting. Potentially effective targeted therapies must be able to penetrate the blood-brain barrier to reach the tumor and, in sufficient concentrations, to result in meaningful treatment responses. Moreover, molecular...